KIT/PDGFRA-IN-3
KIT/PDGFRA-IN-3 is a KIT and PDGFRA mutant kinase inhibitor, with an IC50 of 9 nM against human PDGFRA. KIT/PDGFRA-IN-3 inhibits the kinase activity of KIT, exhibiting superior selectivity for mutant KIT over wild-type KIT. KIT/PDGFRA-IN-3 suppresses the kinase activity of PDGFRA and blocks downstream signaling pathways. KIT/PDGFRA-IN-3 can be used in studies of gastrointestinal stromal tumors.
For research use only. We do not sell to patients.
- Formula: C30H36FN7O4
- Molecular Weight:577.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PDGFRa 9 nM (IC50) |
KIT |
In Vitro
KIT/PDGFRA-IN-3 (compound 44) (0.5 h) achieves potent, mutant-selective kinase inhibition against KIT-D816H with minimal activity against wild-type KIT, supporting its role as a selective inhibitor of oncogenic KIT/PDGFRA variants[1].
KIT/PDGFRA-IN-3 exhibits exceptionally high cellular potency and excellent target selectivity against PDGFRAD842V dependent GIST cells, with very low activity in non-KIT/PDGFRA-driven control cells[1].
KIT/PDGFRA-IN-3 (10-300 nM; 24 h) engages PDGFRAD842V in intact GIST cells at low nanomolar concentrations to potently block oncogenic downstream signal transduction[1].
KIT/PDGFRA-IN-3 (10 μM; 20 h) exhibits a highly reduced off-target phenotypic profile in non-oncogene-driven U2OS cells, indicating a low propensity for global cellular pathway perturbation and improved selectivity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:T1-a-D842V PDGFRA mutant GIST cells
-
Concentration:10 nM; 30 nM; 100 nM; 300 nM
-
Incubation Time:24 h
-
Result:Achieved strong suppression of phospho-PDGFRA at 10-30 nM.
Effectively reduced phosphorylation of the downstream AKT, MAPK, and S6 signaling proteins.
Chemical Information
-
Molecular Weight 577.65
-
Formula C30H36FN7O4
-
SMILES
C[C@](C1=CC=C(F)C=C1)(C2=CN=C(N3CCN(C4=C5C=C(OCCOC)C(OCCOC)=CC5=NC=N4)CC3)N=C2)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)